Objectives

The global population of NASH (now recommended to be termed metabolic dysfunction-associated steatohepatitis; referred to here as NASH throughout for consistency with the terms used in the survey) is rapidly increasing,¹ although the true prevalence may be underestimated due to the lack of perceived symptoms in early stages of the disease²
NASH has a substantial impact on patients’ health-related quality of life;^3–5 however, a gap remains in quantifying patients’ experiences and emotions throughout disease progression
This survey assessed primary experiences, emotions, and unmet needs of patients with NASH and patient caregivers